PR89752

TIANJIN, China, May 27, 2021 /PRNewswire=KYODO JBN/ --

SINOMED, a leading international medical device company, today announced

results from the HT Supreme(TM) Healing-Targeted Drug-Eluting Stent (DES), in

complex patients compared to the Xience or Promus family of DES.  One-year

results were presented at last week's 2021 EuroPCR annual congress showing that

the two devices have similar clinical safety and effectiveness.

The PIONEER III study enrolled 1,629 patients (randomized 2:1 experimental to

control) from North America, Europe and Japan, where the complex patient

subgroup showed similar rates of target lesion failure (TLF) at one-year.  

Patients were considered complex based on AHA/ACC B2/C-criteria. HT Supreme had

a TLF of 5.8% compared to 5.9% in the control arm, with no statistical

difference.  Additionally, long lesions, severe calcification and severe

tortuosity showed no difference between the two arms.

"The one-year target lesion failure rates of the HT Supreme are very low and

compared favourably to current best-in-class devices," said Prof. Andreas

Baumbach from Queen Mary University of London, United Kingdom, and European

co-primary investigator of the PIONEER III trial. "It is important for

clinicians to understand how new devices perform in more complex lesion; as

this is a reflection of the patients we treat day-to-day."

"As we progress our clinical program and continue to see the same, safe and

consistent data from trial to trial, we are convinced that our healing-targeted

stent is the right approach," said Dr. Jianhua Sun, PhD., chairman and chief

executive officer of SINOMED.  "Ensuing that all patient types have another

safe option is a true benefit."

More information on the PIONEER III study is available at

www.clinicaltrials.gov, identifier: NCT03168776.

About the HT Supreme Drug-Eluting Stent:

The HT Supreme represents a novel class of stents that highlights the

importance of early, timely healing.  Through patented designs and proprietary

processes, the HT Supreme is tailored to help patients accelerate their

wound-healing process and restore their naturally protective vessel function.  

This healing-targeted mechanism may help overcome the long-standing problem of

tradition-DES implantation, allowing for safer long-term results.

About SINOMED

SINOMED is a global medical device company engaged in research, development,

production, and commercial distribution of interventional devices. We are

focused on developing breakthrough technologies to target unmet clinical needs

in the interventional treatment of coronary, neurovascular and structural heart

disease. Our mission is to expose more patients to the benefits of our medical

innovations, increasing patient longevity and quality of life.  For more

information visit www.sinomed.com.

SINOMED B.V

Cindy Zheng

T:  +31 10 307 6295

E:  cindy.zheng@sinomed-eu.com  

Photo - https://mma.prnewswire.com/media/1519333/SINOMED_HT_Supreme.jpg

Logo - https://mma.prnewswire.com/media/1333950/SINOMED_Logo.jpg

Source: SINOMED